United Health Products, Inc. has received formal approval from the U.S. Food and Drug Administration for a proposed plan to address a Warning Letter issued in March 2025. The FDA approved the company's proposal to collaborate with another U.S. manufacturer and distributor of hemostatic products, who will serve as the Sponsor of a new clinical study for UHP's CelluSTAT Hemostatic Gauze. This arrangement grants UHP an exclusive right of reference to all data from the study for use in a revised Premarket Approval application, allowing a study to proceed while the company works to resolve the Warning Letter.
The Warning Letter, issued on March 25, 2025, identified violations that occurred during the company's 2019 clinical trial. The newly approved plan represents a significant regulatory milestone after 14 months of investigation and discussion with the FDA. In addition to the clinical study arrangement, the FDA has approved an external audit firm to conduct a Good Clinical Practices audit of UHP's protocols, procedures, and personnel. This audit, recommended by the FDA, aims to assess and confirm the company's ability to conduct its own clinical trials in accordance with FDA regulations and is scheduled for the coming months.
Bran Thom, UHP's CEO, stated that these developments provide a clear path to demonstrating the safety and effectiveness of CelluSTAT gauze through a new Investigational Device Exemption study. The company is currently in discussions with several established medical device companies regarding the substitute sponsor plan and hopes to enter a formal collaboration agreement soon. The GCP audit, along with other proposed corrective actions, is expected to resolve and lift the Warning Letter. For more information, visit https://www.uhpcorp.com.
The implications of this regulatory progress are substantial for the medical device industry and potential patients. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding, and UHP is seeking approval to access the human surgical market. Successful resolution of the Warning Letter and completion of the new clinical study could pave the way for FDA approval, introducing a new hemostatic option to the market. This development highlights the rigorous regulatory pathway for medical devices and the collaborative measures sometimes necessary to address compliance issues while advancing product development.
